OBJECTIVES: To assess the clinical characteristics of patients with RA who received a biologic monotherapy (Mono) and biologic combination therapy (Combo: Biologic+DMARDs) in the US. METHODS:  A multi-country multi-center medical chart-review study of RA patients was conducted between Nov2012-Jan2013 among physicians (mainly rheumatologists) in hospitals and private practices to collect de-identified data on patients who were recently treated with a biologic as part of usual care. Physicians were screened for duration of practice (3-30 yrs) and patient volume (incl. >2RA biologic patients/week) and recruited from a large panel to be geographically representative of the US. Eligible patient charts (>5) were randomly selected from a sample of prospective patients visiting each center/practice during the screening period. Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status. This analysis focused on patients currently on Mono and Combo biologics. RESULTS: st-line-80%/70%, 2^nd-line-15%/20%, >=3^rd-line-5%/11%; top-4 biologics used across the two patient groups were: adalimumab/etanercept/infliximab/abatacept. Among patients with data-availability, current lab & disease-severity measures were (Mono/Combo): ESR(mm/h)-23.7/25.0; CRP(mg/dl)-2.6/3.4; rheumatoid factor (positive%):38%/54%; anti-CCP (positive%):31%/45%; overall disease-stage per physician-judgment: mild-67%/62%, moderate-29%/33%, severe-4%/5%; mean-HAQ:0.7/0/9; mean-DAS28:2.3/3.0; mean tender joint count: 2/3/3.4; mean swollen joint count:1.4/2.5. CONCLUSIONS: In this cohort of RA patients in the US, over 60% of Mono and Combo patients had mild disease per physician judgment and a majority of them were on 1^st line treatment; lab measures and joint counts indicated only slightly higher disease burden among Combo patients. Impact of specific biologic treatments on observed patterns and the need for therapeutic sequencing may warrant scrutiny.